Joshua K Tay

Dr. Joshua K Tay

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
HSHaosheng Shen
Haosheng Shen
CZChangyu Zhang
Changyu Zhang
SLShengjie Li
Shengjie Li
YLYuanmei Liang
Yuanmei Liang
LLLi Ting Lee
Li Ting Lee
MCMatthew Wook Chang
Matthew Wook Chang
Prodrugs have been explored as an alternative to conventional chemotherapy; however, their target specificity remains limited. The tumor microenvironment harbors a range of microorganisms that potentially serve as tumor-targeting vectors for delivering prodrugs. In this study, we harness bacteria-cancer interactions native to the tumor microbiome to achieve high target specificity for prodrug delivery. We identify an oral commensal strain of Lactobacillus plantarum with an intrinsic cancer-binding mechanism and engineer the strain to enable the surface loading of anticancer prodrugs, with nasopharyngeal carcinoma (NPC) as a model cancer. The engineered commensals show specific binding to NPC via OppA-mediated recognition of surface heparan sulfate, and the loaded prodrugs are activated by tumor-associated biosignals to release SN-38, a chemotherapy compound, near NPC. In vitro experiments demonstrate that the prodrug-loaded microbes significantly increase the potency of SN-38 against NPC cell lines, up to 10-fold. In a mouse xenograft model, intravenous injection of the engineered L. plantarum leads to bacterial colonization in NPC tumors and a 67% inhibition in tumor growth, enhancing the efficacy of SN-38 by 54%.

9 November 2019 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
JTJoshua K Tay
Joshua K Tay
CSChor H. Siow
Chor H. Siow
HGHan L. Goh
Han L. Goh
CLChwee M. Lim
Chwee M. Lim
PHPon P. Hsu
Pon P. Hsu
KLKwok S. Loh
Kwok S. Loh

8 April 2022 in Science Advances
Verified
Journal Article
Open access
JTJoshua K Tay
Joshua K Tay
CZChunfang Zhu
Chunfang Zhu
JSJune Ho Shin
June Ho Shin
SZShirley X. Zhu
Shirley X. Zhu
SVSushama Varma
Sushama Varma
RWRobert B. West
Robert B. West
Nasopharyngeal cancer (NPC) is an Epstein-Barr virus (EBV)–positive epithelial malignancy with an extensive inflammatory infiltrate. Traditional RNA-sequencing techniques uncovered only microenvironment signatures, while the gene expression of the tumor epithelial compartment has remained a mystery. Here, we use Smart-3SEQ to prepare transcriptome-wide gene expression profiles from microdissected NPC tumors, dysplasia, and normal controls. We describe changes in biological pathways across the normal to tumor spectrum and show that fibroblast growth factor (FGF) ligands are overexpressed in NPC tumors, while negative regulators of FGF signaling, including SPRY1, SPRY2, and LGALS3, are down-regulated early in carcinogenesis. Within the NF-κB signaling pathway, the critical noncanonical transcription factors, RELB and NFKB2, are enriched in the majority of NPC tumors. We confirm the responsiveness of EBV-positive NPC cell lines to targeted inhibition of these pathways, reflecting the heterogeneity in NPC patient tumors. Our data comprehensively describe the gene expression landscape of NPC and unravel the mysteries of receptor tyrosine kinase and NF-κB pathways in NPC.

24 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
LSLuvita Suryani
Luvita Suryani
HLHazel P. Y. Lee
Hazel P. Y. Lee
Wei Keat TeoWei Keat Teo
Wei Keat Teo
ZCZhi Kang Chin
Zhi Kang Chin
KLKwok Seng Loh
Kwok Seng Loh
JTJoshua K Tay
Joshua K Tay
Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV) driven malignancy arising from the nasopharyngeal epithelium. Current treatment strategies depend on the clinical stage of the disease, including the extent of the primary tumour, the extent of nodal disease, and the presence of distant metastasis. With the close association of EBV infection with NPC development, EBV biomarkers have shown promise in predicting treatment outcomes. Among the omic technologies, RNA and miRNA signatures have been widely studied, showing promising results in the research setting to predict treatment response. The transformation of radiology images into measurable features has facilitated the use of radiomics to generate predictive models for better prognostication and treatment selection. Nonetheless, much of this work remains in the research realm, and challenges remain in clinical implementation.

15 October 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
WCWan Qin Chong
Wan Qin Chong
CLChwee Ming Lim
Chwee Ming Lim
ASArvind Kumar Sinha
Arvind Kumar Sinha
CTChee Seng Tan
Chee Seng Tan
GCGloria Hui Jia Chan
Gloria Hui Jia Chan
BGBoon Cher Goh
Boon Cher Goh
Purpose: Induction cisplatin and gemcitabine chemotherapy is a standard treatment for locally advanced NPC. Inhibition of VEGF axis has been shown to promote maturation of microvasculature and improve perfusion. We conducted a four-arm study to assess the effect of 2 doses of either sunitinib or bevacizumab with chemotherapy in NPC. Experimental Design: Patients with treatment naïve locally advanced NPC were treated with 3 cycles of 3-weekly cisplatin and gemcitabine preceded by 1 week of anti-VEGF therapy for each cycle, followed by standard concurrent chemoradiation: Arm A patients received 7 days of 12.5mg/day sunitinib; Arm B 7 days of 25mg/day sunitinib; Arm C bevacizumab 7.5mg/kg infusion; Arm D bevacizumab 2.5mg/kg infusion. Patients with metastatic NPC were treated with up to 6 cycles of similar treatment without concurrent chemoradiation. Results: Complete metabolic response (mCR) by whole body 18fluorodeoxyglucose PET was highest in Arm C (significant difference in 4 groups Fisher's exact test p=0.001; type 1 error=0.05), with 42% mCR (95% CI 18 - 67) and 3-year relapse free survival of 88% in patients with locally advanced NPC. Significant increase in pericyte coverage signifying microvascular maturation and increased immune cell infiltration was observed in post treatment tumor biopsies in Arm C. Myelosuppression was more profound in sunitinib containing arms, and tolerability was established in Arm C where hypertension was the most significant toxicity. Conclusion: Bevacizumab 7.5mg/kg with cisplatin and gemcitabine was well tolerated. Promising tumour response was observed and supported mechanistically by positive effects on tumour perfusion and immune cell trafficking into the tumour.

1 April 2025 in European Journal of Cancer
Verified
Journal Article
Open access
JNJialing Neo
Jialing Neo
EOEnya H.W. Ong
Enya H.W. Ong
XZXin Zhang
Xin Zhang
WCWen Min Chow
Wen Min Chow
JWJoseph T.S. Wee
Joseph T.S. Wee
MCMelvin LK Chua
Melvin LK Chua
Plasma Epstein-Barr virus (EBV) DNA is an archetypal biomarker for endemic nasopharyngeal carcinoma (NPC) employed for disease surveillance and early detection of recurrences. However, its accuracy is unknown. We utilised a single institution dataset with homogeneous surveillance procedures and routine EBV DNA testing using a harmonised assay to investigate its accuracy for recurrence detection. We utilised a cohort of patients with histologically-confirmed, non-metastatic NPC treated from February, 2017 to July, 2023. All patients had ≥ 1 EBV DNA test using the harmonised BamHI-W polymerase chain reaction-based assay within 3 years post-radiotherapy (RT). We analysed the negative (NPV) and positive predictive values (PPV) for recurrence over a 1-year window (at 3-monthly intervals - windows 1-4) for each test performed. Recurrence was ascertained by radiological imaging and/or histopathological confirmation. Of 1746 EBV DNA readings from 393 patients diagnosed between January, 2017 to May, 2023, 1385 (79.3 %), 294 (16.8 %), and 67 (3.9 %) were recorded as negative, low (< 500 copies/mL), and high EBV DNA (≥ 500 copies/mL), respectively. NPVs of the assay were high (range: 97.6-99.3 %). PPVs were modest, highest at window 1 (range: 26.3-34.3 %) compared with the other 3 windows (range: 2.6-10.5 %). Sensitivity analyses revealed that PPVs were threshold-dependent; 71.4-100 % at window 1 for ≥ 500 copies/mL versus 16.9-23.1 % for < 500 copies/mL, which corresponded to median time of recurrence onset (0.8 vs 4.8 months, respectively). Negative EBV DNA test results have high NPVs, suggesting that patients may be routinely surveyed, while a positive result of ≥ 500 copies/mL indicates high recurrence risk.